Cases Journal

, 3:76 | Cite as

Acute superior mesenteric venous thrombosis with advanced gastric cancer: a case report

  • Fuminori Goda
  • Hiroyuki Okuyama
  • Ayumu Yamagami
  • Hiromi Nakata
  • Michio Inukai
  • Eiji Ohashi
  • Takeaki Kohno
  • Takashi Himoto
  • Hisashi Masugata
  • Shoichi Senda
Open Access
Case Report


Although the advanced stages of neoplasms have a risk of superior mesenteric venous thrombosis (MVT), an initial clinical diagnosis of MVT is sometimes difficult and it can be treated as a cancer-related pain using NSAIDs and/or opioids.

We herein present a case of palliative stage of cancer with acute MVT, which was successfully treated with immediate anticoagulant therapy. We believe this case provides an important clinical lesson, which is that we should remember that MVT is one of the potential causes of abdominal pain with cancer patients and the thrombosis can be easily identified by US and CT.


Advanced Gastric Cancer Anticoagulant Therapy Superior Mesenteric Vein Dalteparin Acute Mesenteric Ischemia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Although the advanced stage of the neoplasm has a risk of superior mesenteric venous thrombosis (MVT) [1], an initial clinical diagnosis of MVT is sometimes difficult and it can be treated as a cancer-related pain. We herein present a case of palliative stage of cancer with acute MVT, which was successfully treated with immediate anticoagulant therapy. His clinical course suggests we should remember that MVT is one of the potential causes of abdominal pain with cancer patients and the thrombosis can be easily identified by US and CT.

Case presentation

A 69-year-old male was admitted because of a continually worsening abdominal cramping pain, which had started two days before his admission. The pain was radiating to his back and it was associated with nausea and appetite loss. The patient had previously undergone a total gastrectomy for advanced gastric cancer two years earlier.

Thereafter, peritoneal relapse occurred and chemotherapy with paclitaxel and S-1 was administered by the outpatient department for six months with uneventfully. At admission, he was fully alert and his vital signs were normal, although he had mild grade fever (37.5°C). On examination, his abdomen was soft and flat with abdominal tenderness at the epigastrium, with diminished bowel sounds. Biochemical results and coagulation studies were within the normal limits. However, his symptoms were getting worse and opioid titillation was thus initiated. He underwent abdominal ultrasonography (US), which showed evidence of thrombosis or tumor thrombosis in the portal vein. A contrast-enhanced CT scan showed evidence of superior mesenteric venous thrombosis associated with thrombosis of the portal vein without cavernous formation(Figure 1). There was no thrombosis in the splenic vein (Figure 2). The dehydration was corrected by the fluid therapy. Anticoagulant therapy was started, because the thrombosis had formed recently and the risk of bleeding was low. The patient was given low-molecular-weight heparin (Dalteparin sodium, Fragmin) at a dosage of 10,000 U per day. Three days after the administration of heparin, he had a complete recovery from abdominal pain without opioid use and was thus able to start eating. He was discharged after 14 days of admission with a shift of the anticoagulant therapy to warfarin with a targeted international normalized ratio (PT-INR) of 1.5-2.0. Three months later, he was doing well and the thrombosis of the superior mesenteric vein and portal vein had completely disappeared on a follow-up CT. Six months later, he died from gastric cancer and the autopsy showed no thrombosis in the superior mesenteric vein and portal vein.
Figure 1

Contrast-enhanced abdominal CT. The thrombosis located in the superior mesenteric vein with portal vein (arrow) without cavernous formation.

Figure 2

Contrast-enhanced abdominal CT. No thrombosis was observed in the splenic vein (arrow).


MVT has been assumed to be a very rare disease. The incidence of MVT was estimated at 1.8-2·7 per 100 000 person-years[2, 3]. This accounts for 1.5-6.2% of patients of acute mesenteric ischemia in various studies[4]. The neoplasm is among the more common causes of mesenteric venous thrombosis. As illustrated in Table 1, 83 (21%) of 395 cases of MVT associated with neoplasm [2, 3, 4, 5, 6, 7]. The advanced stage of the neoplasm has a risk of developing MVT such as, hyper-coagulability, a low flow state in the superior mesenteric vein as a result of dehydration and chemotherapy [5, 8, 9].
Table 1

Incidence of Cancer relative MVT




cancer related cases

Acosta, S(2005) [2]



8 (35%)

Acosta, S(2008) [3]



12 (24%)

Kumar, S(2003) [4]



9 (13%)

Janssen, HL(2001)[5]




Sogaard K(2001)[6]



9 (13%)

Morasch, MD(2001)[7]



4 (31%)




83 (21%)

The clinical diagnosis of MVT associated with a neoplasm is sometimes difficult. The symptoms and signs of MVT are non-specific, such as abdominal pain with nausea, vomiting, diarrhea/constipation and fever [4], and the initial physical findings may often appear to be entirely normal. These conditions are often assumed to be cancer related symptoms, which can be treated with NSAIDs and/or opioids. In the present case, the initial diagnosis was cancer-related pain during chemotherapy for gastric cancer with peritonitis carcinomatosa.

The use of advanced imaging techniques provided useful and helpful information. US is a powerful modality for the screening of a suspected thrombosis. Contrast-enhanced CT, which facilitates the early and accurate detection of thrombosis, including fresh thrombosis with a high sensitivity [4], therefore indicated the precise location of the thrombosis and the duration of the thrombosis in this case.

The best strategy for MVT is its early diagnosis and immediate treatment [1]. Anticoagulant therapy, which generally allows for the re-canalization of the thrombosed vein in recently formed thromboses, is recommended in patients with acute MVT to improve the survival without increasing the risk of bleeding [4, 10], however, reliable data for the palliative stage of cancer patients with MVT is still scarce.


The palliative stage of a cancer patient with MVT was successfully treated. It is important to remember that MVT is one of the causes of abdominal pain in cancer patients and such thrombosis can be easily identified by both US and CT. Even in palliative stage cancer patients, the immediate use of anticoagulants can improve both the QOL and the prognosis of the patients.


Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.


Supplementary material

13257_2009_1561_MOESM1_ESM.tiff (1.1 mb)
Authors’ original file for figure 1
13257_2009_1561_MOESM2_ESM.tiff (1.1 mb)
Authors’ original file for figure 2


  1. 1.
    Kumar S, Sarr MG, Kamath PS: Mesenteric venous thrombosis. N Engl J Med. 2001, 345: 1683-8. 10.1056/NEJMra010076.CrossRefPubMedGoogle Scholar
  2. 2.
    Acosta S, Ogren M, Sternby NH, Bergqvist D, Bjorck M: Mesenteric venous thrombosis with transmural intestinal infarction: a population-based study. J Vasc Surg. 2005, 41: 1683-8. 10.1016/j.jvs.2004.10.011.CrossRefGoogle Scholar
  3. 3.
    Acosta S, Alhadad A, Svensson P, Ekberg O: Epidemiology, risk and prognostic factors in mesenteric venous thrombosis. Br J Surg. 2008, 95: 1245-51. 10.1002/bjs.6319.CrossRefPubMedGoogle Scholar
  4. 4.
    Kumar S, Kamath PS: Acute superior mesenteric venous thrombosis: one disease or two?. Am J Gastroenterol. 2003, 98: 1299-304. 10.1111/j.1572-0241.2003.07338.x.CrossRefPubMedGoogle Scholar
  5. 5.
    Janssen HL, Wijnhoud A, Haagsma EB, van Uum SH, van Nieuwkerk CM, Adang RP, Chamuleau RA, van Hattum J, Vleggaar FP, Hansen BE, Rosendaal FR, van Hoek B: Extrahepatic portal vein thrombosis: aetiology and determinants of survival. Gut. 2001, 49: 720-4. 10.1136/gut.49.5.720.PubMedCentralCrossRefPubMedGoogle Scholar
  6. 6.
    Sogaard KK, Astrup LB, Vilstrup H, Gronbaek H: Portal vein thrombosis; risk factors, clinical presentation and treatment. BMC Gastroenterol. 2007, 7: 34-10.1186/1471-230X-7-34.PubMedCentralCrossRefPubMedGoogle Scholar
  7. 7.
    Morasch MD, Ebaugh JL, Chiou AC, Matsumura JS, Pearce WH, Yao JS: Mesenteric venous thrombosis: a changing clinical entity. J Vasc Surg. 2001, 34: 680-4. 10.1067/mva.2001.116965.CrossRefPubMedGoogle Scholar
  8. 8.
    Brisse H, Orbach D, Lassau N, Servois V, Doz F, Debray D, Helfre S, Hartmann O, Neuenschwander S: Portal vein thrombosis during antineoplastic chemotherapy in children: report of five cases and review of the literature. Eur J Cancer. 2004, 40: 2659-66. 10.1016/j.ejca.2004.06.013.CrossRefPubMedGoogle Scholar
  9. 9.
    Feenstra J, Vermeer RJ, Stricker BH: Mesenteric venous thrombosis attributed to docetaxel. Am J Clin Oncol. 2000, 23: 353-4. 10.1097/00000421-200008000-00008.CrossRefPubMedGoogle Scholar
  10. 10.
    Spanier BW, Frederiks J: Aetiology of extrahepatic portal vein thrombosis. Gut. 2002, 51: 755-6. 10.1136/gut.51.5.755-b.PubMedCentralCrossRefPubMedGoogle Scholar

Copyright information

© Goda et al; licensee BioMed Central Ltd. 2010

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Authors and Affiliations

  • Fuminori Goda
    • 1
  • Hiroyuki Okuyama
    • 2
  • Ayumu Yamagami
    • 1
  • Hiromi Nakata
    • 2
  • Michio Inukai
    • 1
  • Eiji Ohashi
  • Takeaki Kohno
    • 2
  • Takashi Himoto
    • 2
  • Hisashi Masugata
    • 2
  • Shoichi Senda
    • 2
  1. 1.Cancer CenterKagawa Medical University HospitalKita-gunJapan
  2. 2.Department of Integrated MedicineKagawa Medical University HospitalKita-gunJapan

Personalised recommendations